Neoadjuvant chemotherapy and surgical considerations in ovarian cancer

Current Opinion in Obstetrics and Gynecology

Volumn 15, Issue 1, 2003, Pages 25-31

  Gallo, Angelo ^a   Frigerio, Luigi ^a  

^a OSPEDALI RIUNITI   (Italy)

Author keywords

Debulking; Interval laparotomy; Neoadjuvant chemotherapy; Ovarian neoplasms; Surgery

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; TAXANE DERIVATIVE;

CANCER ADJUVANT THERAPY; CANCER REGRESSION; CANCER SURGERY; CANCER SURVIVAL; FEMALE; HUMAN; LAPAROTOMY; MORBIDITY; OUTCOMES RESEARCH; OVARY CANCER; OVARY CARCINOMA; PATIENT SELECTION; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; REVIEW;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOPSY, NEEDLE; COMBINED MODALITY THERAPY; FEMALE; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; OVARIAN NEOPLASMS; OVARIECTOMY; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS; RISK ASSESSMENT; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0037307104     PISSN: 1040872X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001703-200302000-00004     Document Type: Review

References (36)

1. Griffiths CT. Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Natl Cancer Inst Monogr 1975; 42:101-104.
2. Le T, Krepart GV, Lotocki RJ, Heywood MS. Does debulking surgery improve survival in biologically aggressive ovarian carcinoma. Gynecol Oncol 1997; 67:208-214.
3. Hoskins WJ, Mc Guire WJ, Brady MF, et al. The effect of diameter of largest residual disease on survival after primary surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol 1994; 170:974-980.
4. Scarabelli C, Gallo A, Franceschi S, et al. Primary cytoreductive surgery with rectosigmoid colon resection for patients with advanced ovarian cancer. Cancer 2000; 88:389-397.
5. Boente MP, Chi DS, Hoskins WJ. The role of surgery in the management of ovarian cancer: primary and interval cytoreductive surgery. Semin Oncol 1998; 25:326-334.
6. Ozols RF, Rubin SC, Thomas GM, Robboj SJ. Epithelial ovarian cancer. In: Principles and practice of gynecologic oncology. Hoskins WY, Perez CA, Young RC (editors). Philadelphia, New York: Lippincott-Raven; 1996. pp. 919-986.
7. Memarzadeh S, Berek JS. Advances in the management of epithelial ovarian cancer. J Reprod Med 2001; 46:621-630. The article is a thoughtful and scholarly review of recent advances in the management of ovarian cancer.
8. Bristow RE, Tomacruz RS, Amstrong DK, et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 2002; 20:1248-1259. During the platinum era, maximal cytoreduction was one of the most powerful determinants of cohort survival among patients with stage III-IV ovarian carcinoma.
9. Hoskins WJ, Bundy BN, Thigpen JT, Omura GA. The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol 1992; 47:159-166.
10. Gadducci A, Sartori E, Maggino T, et al. Analysis of failures after negative second look in patients with advanced ovarian cancer: an Italian multicenter study. Gynecol Oncol 1998; 68:150-155.
11. Pecorelli S, Odicino F, Favalli G. Ovarian cancer: best timing and applications of debulking surgery. Ann Oncol 2000; 11 (Suppl 3):141-144.
12. Huober J, Meyer A, Wagner U, Wallwiener D. The role of neoadjuvant chemotherapy and interval laparotomy in advanced ovarian cancer. J Cancer Res Clin Oncol 2002; 128:153-160. This excellent review analyses numerous trials evaluating the feasibility and efficiency of the use of primary chemotherapy followed by interval laparotomy in women with advanced ovarian cancer.
13. Van der Burg MEL, van Lent M, Buyse M, et al. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. N Engl J Med 1995; 332:629-634.
14. Redman CWE, Warwick J, Luesley DM, et al. Intervention debulking surgery in advanced epithelial ovarian cancer. Br J Obstet Gynecol 1994; 101:142-146.
15. Rose PG, Nerenstone S, Brady M, et al. A phase III randomised study of interval secondary cytoreduction in patients with advanced stage ovarian carcinoma with suboptimal residual disease: a Gynecologic Oncology Group study. Proc Am Soc Clin Oncol 2002; 21:201a.
16. Wils J, Blijham A, Naus A, et al. Primary or delayed debulking surgery and chemotherapy consisting of cisplatin, doxorubicin, and cyclophosphamide in stage III-IV epithelial ovarian carcinoma. J Clin Oncol 1986; 4:1068-1073.
17. Lawton FG, Redman CWE, Luesley DM, et al. Neoadjuvant (cytoreductive) chemotherapy combined with intervention debulking surgery in advanced, unresected epithelial ovarian cancer. Obstet Gynecol 1989; 73:61-65.
18. Neijt JP, ten Bokkel Huinik WW, van der Burg MEL, et al. Randomized trial compared two combination chemotherapy regimens (CHAP-5 vs CP) in advanced ovarian carcinoma. J Clin Oncol 1987; 5:1157-1168.
19. Lim JTW, Green JA. Neoadjuvant carboplatin and ifosfamide chemotherapy for inoperable FIGO stage III and IV ovarian carcinoma, Clin Oncol 1993; 5:198-202.
20. Ng LW, Rubin SC, Hoskins WJ, et al, Aggressive chemosurgical debulking in patients with advanced ovarian cancer. Gynecol Oncol 1990; 38:358-363.
21. Jacob JH, Gershenson DM, Morris M, et al. Neoadjuvant chemotherapy and interval debulking for advanced epithelial ovarian cancer. Gynecol Oncol 1991; 42:146-150.
22. Huober J, Bastert G, Meyer A, et al, Primary dose intensified chemotherapy with cisplatin and treosulfam in advanced ovarian cancer. J Cancer Res Clin Oncol 2000; 126:Abstract 80.
23. Tournigand C, Louvet C, Molitor JL, et al. Intravenous chemotherapy, early debulking surgery, and consolidation intraperitoneal chemotherapy in advanced ovarian carcinoma. Gynecol Oncol 2001; 83:198-204. The prognosis of patients with advanced ovarian carcinoma may be improved by a sequential treatment strategy including intravenous chemotherapy, early debulking surgery, and intraperitoneal chemotherapy.
24. Stuart G, Bertelsen K, Mangioni C, et al. Updated analysis shows a highly significant improved overall survival (OS) forcisplatin-paclitaxel as first line treatment of advanced ovarian cancer: mature results of the EORTC-GCCG, NOCOVA, NCIC CTG and Scottish Intergroup Trial [Abstract]. Proc Am Soc Clin Oncol 1998; 17:361a.
25. Vermorken JB, Pecorelli S. Clinical trials in patients with epithelial ovarian cancer: past, present and future. Eur J Surg Oncol 1996; 22:455-466.
26. Romagnolo C, Gadducci A, Zola P, et al. Serum half life of CA 125 during early chemotherapy as an independent prognostic variable for patients with advanced epithelial ovarian cancer: results of a multicentric Italian study [Abstract]. Anticancer Res 1995; 15:1765-1766.
27. Chambers JT, Chambers SK, Voynick IM, Schwartz PE. Neoadjuvant chemotherapy in stage X ovarian carcinoma. Gynecol Oncol 1990; 37:327-331.
28. Surwit E, Childers I, Atlas I, et al. Neoadjuvant chemotherapy for advanced ovarian cancer. Int J Gynecol Cancer 1996; 6:356-361.
29. Schwartz PE, Rutherford TJ, Chambers JT, et al. Neoadjuvant chemotherapy for advanced ovarian cancer: long term survival. Gynecol Oncol 1999; 72:93-99.
30. Nelson BE, Rosenfield AT, Schwartz PE, Preoperative abdominoopelvic computed tomographic prediction of optimal cytoreduction in epithelial ovarian carcinoma. J Clin Oncol 1993; 11:166-172.
31. Eisenkop SM, Friedman RL, Wang H. Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study. Gynecol Oncol 1998; 69:103-106.
32. Le T, Krepart GV, Lotocki RJ, et al. Does debulking surgery improve survival in biologically aggressive ovarian cancer? Gynecol Oncol 1997; 67:208-218.
33. Eisenkop SM, Spirtos NM, Friedman RL. Neoadjuvant chemotherapy for advanced ovarian cancer. Gynecol Oncol 1999; 74:311-313.
34. Ansquer Y, Leblanc E, Clough K, et al. Neoadjuvant chemotherapy for unresectable ovarian carcinoma. A French multicenter study. Cancer 2001; 91:2239-2334. Neoadjuvant chemotherapy for primary unresectable ovarian carcinoma leads to the selection of a subset of patients sensitive to chemotherapy, in whom optimal cytoreduction can be achieved after chemotherapy by standard surgery in a high proportion of cases.
35. Kayikciog Lu F, Kose MF, Boran N, et al. Neoadjuvant chemotherapy or primary surgery in advanced epithelial ovarian carcinoma. Int J Gynecol Cancer 2001; 11:466-470. Primary chemotherapy followed by interval debulking surgery in a selected group of patients does not appear to worsen prognosis, but permits less aggressive surgery and improves the patient's quality of life.
36. Kuhn W, Rutke S, Spathe K, et al. Neoadjuvant chemotherapy followed by tumor debulking prolongs survival for patients with poor prognosis in International Federation of Gynecology and Obstetrics Stage IIIC ovarian carcinoma. Cancer 2001; 92:2585-2591. Patients with advanced ovarian carcinoma of FIGO stage IIIC who will benefit only marginally from conventional therapy can be identified by the evidence of a large ascites volume. Higher tumour resection rates and longer median survivals can be achieved in these patients by the use of neoadjuvant chemotherapy.